The US Food and Drug Administration (FDA) has granted investigational new drug approval (IND) to France-based Sensorion to proceed with SENS-401, based on preclinical data and clinical development plan, it was reported yesterday.
SENS-401 is under development for the treatment of Sudden Sensorineural Hearing Loss (or SSNHL). The product, arazasetron besylate, is a drug candidate that intends to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
The company started the Phase two clinical trial in this indication in 2019 in Europe, Canada, Israel and Turkey. The interim safety results are likely to be revealed at the end of 2019 and top line data will be announced mid-2020.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML